Skip to main content

Nuvectis Pharma, Inc.

NVCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001875558

No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q3 2026, worth $272.1M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$697.8M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +13 vs. previous quarter
94
13F valueReported value at the end of Q3 2026
$272.1M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$26.4M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.54M
Shares sold short
Change
+144.1K
+6.0% vs. previous
Days to cover
15.16
At average daily volume

Superinvestors holding NVCT, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding NVCT at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Nuvectis Pharma, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 1, 2026 (view filing)1:41 PM ETJun 301 dayMosseri Marlio Charles10% OwnerPPurchase+50.0K$18.32+$916.0K+1.6%3.19M after
Jul 1, 2026 (view filing)1:39 PM ETJun 301 dayBentsur RonChairman & CEOPPurchase+12.5K$20.00+$250.0K+0.3%3.69M after
Nov 6, 2025 (view filing)Nov 51 dayBentsur RonChairman & CEOPPurchase+5.00K$5.72+$28.6K+0.1%3.53M after
Nov 6, 2025 (view filing)Nov 51 daySanchez JuanDirectorPPurchase+13.0K$5.79+$75.3K+20.0%78.2K after
Nov 6, 2025 (view filing)Nov 51 dayKaplan Matthew L.DirectorPPurchase+11.0K$5.84+$64.2K+9.7%124.8K after
Oct 29, 2025 (view filing)Oct 23-276 daysLateMosseri Marlio Charles10% OwnerPPurchase+154.8K$6.18+$957.1K+5.2%3.14M after3 lots
Jun 24, 2025 (view filing)Jun 204 daysMosseri Marlio Charles10% OwnerPPurchase+5.60K$7.99+$44.8K+0.2%2.98M after
Jun 20, 2025 (view filing)Jun 17-183 daysMosseri Marlio Charles10% OwnerPPurchase+33.4K$8.06+$269.5K+1.1%2.98M after2 lots
May 13, 2025 (view filing)May 121 dayMosseri Marlio Charles10% OwnerPPurchase+21.2K$8.11+$171.7K+0.7%2.94M after
May 12, 2025 (view filing)May 8-94 daysMosseri Marlio Charles10% OwnerPPurchase+27.7K$8.94+$247.3K+1.0%2.94M afterAmended6 lots

Top 10 13F holders, Q3 2026

See all 94 holders

The largest institutional positions in Nuvectis Pharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding NVCT in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Soleus Capital Management, L.P.1,710,658$36.1M1.28%+710,658+71.1%Added
Tang Capital Management LLC1,577,968$33.3M1.53%+27,968+1.8%Added
Braidwell LP1,573,823$33.2M1.38%+1,573,823New
BlackRock, Inc.1,306,975$27.6M0.00%+305,690+30.5%Added
Vanguard Capital Management LLC907,271$19.2M0.00%+34,789+4.0%Added
Iridian Asset Management LLC793,207$16.8M6.09%+16,129+2.1%Added
Geode Capital Management, LLC503,368$10.6M0.00%+71,095+16.4%Added
Parkman Healthcare Partners LLC425,351$8.98M0.81%+425,351New
Baldwin Brothers Inc382,015$8.07M0.53%00.0%Unchanged
State Street Corp368,995$7.79M0.00%+120,797+48.7%Added

Holders of 5% or more of NVCT

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nuvectis Pharma, Inc..

Largest holders of NVCT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Soleus Private Equity Fund III, L.P.13G5.10%1.65M sharesNewAug 6, 20261 filingAug 6, 2026SEC